SCHEMBL14902309

SCHEMBL14902309

CC/C(O)=C/C(=O)N1CCC(O)CC1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.37
NPC1 O15118 3/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
GRM5 P41594 1/20 0.33
EPHX2 P34913 2/20 0.33
HTT P42858 1/20 0.32
CPN1 P15169 1/20 0.32
CPB2 Q96IY4 1/20 0.32
GAA P10253 2/20 0.32
ALDH1A1 P00352 1/20 0.32
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19621347 0.81 NPC1 (0.37) DPP4NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL14902310 0.78 HTT (0.46) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL27805794 0.77 DPP4 (0.39) DPP4NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL20924843 0.75 MAPT (0.45) NPC1RAB9ASMN1; SMN2TDP1GAA
SCHEMBL14902312 0.74 DPP4 (0.37) DPP4NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL7487836 0.74 EPHX2 (0.53) DPP4NPC1EPHX2ALDH1A1
SCHEMBL6417751 0.74 GRM5 (0.38) DPP4NPC1RAB9ALMNAGRM5
Butane SCHEMBL27881893 0.72 DPP4 (0.41) DPP4NPC1RAB9ALMNATDP1
SCHEMBL14562577 0.71 NPC1 (0.39) DPP4NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL2941527 0.70 TEAD1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394324-B2 Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias VIFOR (INTERNATIONAL) AG (CH) 2016-07-19 US disclosed
US-20130109662-A1 Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias VIFOR (INTERNATIONAL) AG (CH) 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109662-A1 Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias FECH, SDHB, SLC40A1 DPP4 3945/4885NPC1 781/4885RAB9A 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.